Previous 10 | Next 10 |
180 Life Sciences (NASDAQ: ATNF) , a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has shared follow-up information regarding its phase 2b clinical trial for Dupuytren’s diseas...
PALO ALTO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases,...
Shares of 180 Life Sciences (ATNF -25.0%) are down significantly today despite releasing top-line phase 2 data yesterday showing the anti-TNF biologic adalimumab met its primary endpoint in a trial for Dupuytren contracture. Volume of ~3.2M shares as of 128p ET today is much higher...
Gainers: Biofrontera (NASDAQ:BFRI) +36%. CF Acquisition (NASDAQ:CFVIU) +19%. Day One (NASDAQ:DAWN) +16%. Terns Pharmaceuticals (NASDAQ:TERN) +15%. Duluth Holdings (NASDAQ:DLTH) +15%. Snowflake (NYSE:SNOW) +14%. Aurinia Pharmaceuticals (NASDAQ:AUPH) +14%. Express (NYSE:EXPR) +13%. Vor Biopharm...
Gainers: Biofrontera (NASDAQ:BFRI) +29%, Terns Pharmaceuticals (NASDAQ:TERN) +20%, Aurinia Pharmaceuticals (NASDAQ:AUPH) +17%, Atreca (NASDAQ:BCEL) +12%, 4D pharma (NASDAQ:LBPS) +9%. Losers: Context Therapeutics (NASDAQ:CNTX) -29%, 180 Life Sc...
180 Life Sciences (NASDAQ: ATNF) , a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that Professor Jagdeep Nanchahal from the University of Oxford, a co-founder of 180 Life ...
According to topline data shared by Oxford University Professor Jagdeep Nanchahal, a Phase 2b clinical trial conducted by 180 Life Sciences (ATNF -8.0%) for anti-TNF biologic adalimumab in Dupuytren’s Disease has met the primary endpoint. In a keynote address titled ‘Re-purposin...
PALO ALTO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases,...
Applied UV (NASDAQ:AUVI) +47%. Skylight Health Group (NASDAQ:SLHG) +27%. Ardelyx (NASDAQ:ARDX) +18%. IceCure Medical (NASDAQ:ICCM) +17%. Energy Focus (NASDAQ:EFOI) +17%. Ambarella (NASDAQ:AMBA) +15% on Q3 results VBI Vaccines (NASDAQ:VBIV) +14% wins FDA approval for Hepatitis B vacc...
180 Life Sciences (NASDAQ:ATNF) has added ~18.3%, and Vaxart (NASDAQ:VXRT) gained ~5.4% in early trading as the two biotechs have sparked significant investor interest on social media platforms. According to data tracking the mentions of ticker symbols on social media, bot...
News, Short Squeeze, Breakout and More Instantly...
180 Life Sciences Corp Com Company Name:
ATNF Stock Symbol:
NASDAQ Market:
180 Life Sciences Corp Com Website:
180 Life Sciences (NASDAQ: ATNF) today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “hearings panel”) of the Nasdaq Stock Market LLC that it has granted the company’s request for additional time to achieve compliance with Nasdaq’...
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq S...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 2.5% to $131.38 on volume of 280,159,738 shares Maxeon Solar Technologies Ltd. (MAXN) fell 8.1% to $0.248 on volume of 217,585,873 shares Tesla Inc. (TSLA) rose 3.7% to $262.33 on volume of 159,323,492 s...